NICE recommends first oral GnRH antagonist for uterine fibroids
The National Institute for Health and Care Excellence (NICE) has published final guidance recommending Ryeqo (relugolix 40mg, estradiol 1mg, and norethisterone acetate 0.5mg), for the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age. The decision makes the relugolix combination therapy… Read More